[16–20] In addition to being the largest series of prospective assessment of mesothelin expression in lung cancer, the strengths of our study include a uniform patient population, all of whom enrolled in a trial of tumor molecular profiling, availability of robust clinical, pathologic, immunohistochemical, and mutational data and long-term follow-up. Here, MSLN is linked to neoplasm.